ETF Watch - In Search of the Healthiest Option: With 160 new ETFs this year alone, picking the best can be tough. Here's how

摘要

UNLESS YOU'RE an expert in metabolic-endocrine disorders, you probably aren't familiar with Emisphere Technologies. A tiny company with 120 employees, Emisphere specializes in oral forms of injectable drugs for diseases such as osteoporosis and diabetes. It posted USD7.2 million in revenue last year and no net income. Yet it's a top holding in a new ETF called the Health-Shares Metabolic-Endocrine Disorders fund, which holds 22 stocks in the same therapeutic field. "Biotech is a hard place to invest in," says Jeff Feldman, chairman of XShares Advisors, the company behind the newfund. That's why, he says, XShares now sponsors 12 disease-specific ETFs, from a "Dermatology and Wound Care" fund to an "Autoimmune-Inflammation" fund.